PURPOSE: We defined a series of clinical trajectories represented among adult patients with new-onset seizures across a 4-year follow-up period; and linked these clinical trajectories to the quality of life (QOL) profiles and trajectories of those experiencing them. We examined both between- and within-group differences. METHODS: Analyses were based on 253 individuals completing QOL questionnaires at baseline and 2 and 4 years subsequently. Based on patient self-report, we defined five "clinical trajectory" groups: individuals experiencing a single seizure only; individuals entering early remission; individuals experiencing late remission; individuals initially becoming seizure-free but subsequently relapsing; individuals with seizures persisting throughout follow-up. QOL profiles at each time point were compared using a validated QOL battery, NEWQOL. KEY FINDINGS: Even at baseline, there were significant between-group differences, with patients experiencing a single seizure only reporting the best QOL profile and those with seizures subsequently persisting across all time points reporting the worst. By 2 years, the QOL profiles of individuals experiencing early remission were similar to those of single seizure patients, as were those for late remission and relapse patients. SIGNIFICANCE: A consistent pattern was seen, with "single seizure" individuals doing best and individuals with persistent seizures doing worst. Of particular concern is that even at baseline, individuals whose seizures persisted were doing poorly for QOL, suggesting the possibility that underlying neurobiologic mechanisms were operating. In contrast, our findings support previous reports of only short-lived and small QOL decrements for individuals experiencing a single or few seizures. Wiley Periodicals, Inc.
PURPOSE: We defined a series of clinical trajectories represented among adult patients with new-onset seizures across a 4-year follow-up period; and linked these clinical trajectories to the quality of life (QOL) profiles and trajectories of those experiencing them. We examined both between- and within-group differences. METHODS: Analyses were based on 253 individuals completing QOL questionnaires at baseline and 2 and 4 years subsequently. Based on patient self-report, we defined five "clinical trajectory" groups: individuals experiencing a single seizure only; individuals entering early remission; individuals experiencing late remission; individuals initially becoming seizure-free but subsequently relapsing; individuals with seizures persisting throughout follow-up. QOL profiles at each time point were compared using a validated QOL battery, NEWQOL. KEY FINDINGS: Even at baseline, there were significant between-group differences, with patients experiencing a single seizure only reporting the best QOL profile and those with seizures subsequently persisting across all time points reporting the worst. By 2 years, the QOL profiles of individuals experiencing early remission were similar to those of single seizure patients, as were those for late remission and relapse patients. SIGNIFICANCE: A consistent pattern was seen, with "single seizure" individuals doing best and individuals with persistent seizures doing worst. Of particular concern is that even at baseline, individuals whose seizures persisted were doing poorly for QOL, suggesting the possibility that underlying neurobiologic mechanisms were operating. In contrast, our findings support previous reports of only short-lived and small QOL decrements for individuals experiencing a single or few seizures. Wiley Periodicals, Inc.
Authors: Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk Journal: Ther Adv Neurol Disord Date: 2016-11-29 Impact factor: 6.570
Authors: Lisa Langenbruch; Julia Krämer; Sati Güler; Gabriel Möddel; Sophia Geßner; Nico Melzer; Christian E Elger; Heinz Wiendl; Thomas Budde; Sven G Meuth; Stjepana Kovac Journal: J Neurol Date: 2019-05-08 Impact factor: 4.849
Authors: Doug Speed; Clive Hoggart; Slave Petrovski; Ioanna Tachmazidou; Alison Coffey; Andrea Jorgensen; Hariklia Eleftherohorinou; Maria De Iorio; Marian Todaro; Tisham De; David Smith; Philip E Smith; Margaret Jackson; Paul Cooper; Mark Kellett; Stephen Howell; Mark Newton; Raju Yerra; Meng Tan; Chris French; Markus Reuber; Graeme E Sills; David Chadwick; Munir Pirmohamed; David Bentley; Ingrid Scheffer; Samuel Berkovic; David Balding; Aarno Palotie; Anthony Marson; Terence J O'Brien; Michael R Johnson Journal: Hum Mol Genet Date: 2013-08-19 Impact factor: 6.150
Authors: Christophe de Bézenac; Marta Garcia-Finana; Gus Baker; Perry Moore; Nicola Leek; Rajiv Mohanraj; Leonardo Bonilha; Mark Richardson; Anthony Guy Marson; Simon Keller Journal: BMJ Open Date: 2019-10-16 Impact factor: 2.692